Zantac And Ranitidine Are Recalled And The Alternatives Are In Short Supply

There are numerous reasons for the run on antacids

Friday, December 11, 2020 - Zantac and other Ranitidine tablets were recalled earlier in 2020 over fears that the tablets contain carcinogenic levels of NDMA which causes cancer. Even the most common antacid tablets like Tums, Pepcid, and its generic version, famotidine is in short supply as it is being hoarded by people that think it will help them better deal with the stress of everything listed above. Also, people including the current President of the United States have used antacids to help them get through having the Corona Virus. According to the New York Times, "Preliminary studies suggested that famotidine, the key ingredient in Pepcid, may reduce coronavirus symptoms, though the medical community remains cautious."

Individuals that have developed cancer and have taken Zantac regularly for many years are filing suit alleging that Zantac contains NDMA, a known carcinogen, at higher than normal levels that could cause cancer. Hundreds of people have already hired Zantac Cancer Lawyers, and thousands more may file once the first round of bellwether Zantac Cancer trials concludes in 2021 or 2022. If you or a loved one have developed cancer and have taken Zantac regularly for more than one year, you should speak with a Zantac Cancer Lawyer to see if you can file a claim. Lawsuits allege that carcinogenic levels of NDMA are a naturally-occurring byproduct of ranitidine (Zantac). About Lawsuits describes a recently filed lawsuit that alleges, " the cancer side effects from Zantac appear to be an inherent byproduct of the active pharmaceutical ingredient in the recalled heartburn drug, ranitidine." If this is true, a large percentage of the 15 million or so Americans that used Zantac regularly may be at risk of developing cancer, yet another episode in the unending string of heartbreaks that have occurred in 2020.

People say that 2020 has been a horrible year and that they can not wait for it to be over. 2021 may be no better, however, and maybe worse as shortages of certain foods like meat and common household items are hoarded and shortages occur. If this second wave of Covid-19 takes hold, Americans may also be faced with losing their jobs or their businesses failing and closing. To make matters worse government stimulus payments postponed real estate mortgage foreclosures until January 2021 which is less than a month away. The US presidential election does not appear to be decided one way or another and one side will be angry if their candidate falls short. All this and the traditional standard American diet (SAD) of high fat, spicy foods, leave people scrambling for an antacid pill that is no longer available.

People are urged to take the symptoms of acid indigestion seriously as the condition could lead to esophageal cancer or other forms of the disease. Those suffering from heartburn or acid reflux should consult their doctors, if possible if an antacid medicine is needed. Some doctors in certain states are limiting their patient visits to those with critical needs only. You should avoid eating spicy foods, smoking, or drinking coffee until able to see a doctor.

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
• Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
• Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
• A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
• Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
• Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
• Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
• Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
• The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
• Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
• Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
• Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
• Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
• Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
• Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
• Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.